Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study

Amy D. Shapiro, Shashikant Apte, Ana Boban, Renée Brown Frandsen, Silvia Linari, Johnny Mahlangu, Camila Martins Mazini Tavares, Tadashi Matsushita, Salim Nekkal, Jameela Sathar, Anthony K C Chan

Blood (2024) 144 (Supplement 1): 715.

https://doi.org/10.1182/blood-2024-209759

Published: 2024

Journal Articles

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Jan Astermark, Shashikant Apte, Chuhl Joo Lyu, Amalie Rhode Høgh Nielsen, Sonata Saulyte Trakymiene, Jay Jay Thaung Zaw, Huyen Tran, Jerzy Windyga, Hermann Eichler

Blood (2023) 142 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2023-173118

Published: 2023

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima

Blood (2021) 138 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2021-144576

Published: 2021

Journal Articles

An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies

Blood (2021) 138 (Supplement 1): 309.

https://doi.org/10.1182/blood-2021-152548

Published: 2021

Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139847

Published: 2020

Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Blood (2019) 134 (Supplement_1): 4158.

https://doi.org/10.1182/blood-2019-129751

Published: 2019

Journal Articles

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Flora Peyvandi, MD PhD, Paolo Bucciarelli, MD, Carla Valsecchi, BSc, Marco Boscarino, Roberta Palla, PhD, Elena Santagostino, Amal El-Beshlawy, Mohsen Saleh Elalfy, MD, Vijay M. Ramanan, MBBS,MDDM, Peyman Eshghi, MD, Suresh Hanagavadi, MD, Mehran Karimi, MD, Cecil Ross, MD, Mamta V Manglani, MD, Guy Young, Tulika Seth, MDMBBS,FAAP, Shashikant Apte, MD FRCPA, Dinesh M Nayak, MD, Maria Elisa Mancuso, Johnny Mahlangu, Bonanad Santiago, MD, Monica H Cerqueira, MD PhD, Nadia P Ewing, MD, Christoph Male, MD, Tarek Owaidah, MDFRCPA, Veronica Soto Arellano, MD, Suvankar Majumdar, MBCHB, Mindy Simpson, MD, Mathew Thomas, MD, Ezio Zanon, Marilyn J Manco-Johnson, MD, Monica Martinez, MD, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Rogelio Alejandro Paredes-Aguilera, MD, Alessandra N L Prezotti, MD MSc, Klaus Schmitt, MD, Bulent Zulfikar, Prof, Pier Mannuccio Mannucci, MD, Frits Richard Rosendaal, MD

Blood (2018) 132 (Supplement 1): 384.

https://doi.org/10.1182/blood-2018-99-114599

Published: 2018

Journal Articles

Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India

Aby Abraham, MD DM, Shashikant Apte, MD FRCPA, Chandrakala Shamukhaiah, MD DM, Fouzia N., DNB, DM, Kannan Subramaniam, DNB, DM, Akshata Rahate, MD DM, Abraham Sunder Singh, BSc, Aditi Joshi, BAMS, Kavitha M Lakshmi, MSc, Rajesh Phatale, MD, Shrimati Shetty, PhD, Sukesh Chandran Nair, MD, Biju George, DM, Vikram Mathews, MD, Alok Srivastava, MD, FRACP,FRCPA

Blood (2018) 132 (Supplement 1): 2494.

https://doi.org/10.1182/blood-2018-99-119279

Published: 2018

Journal Articles

Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach

Shashikant Apte, MD FRCPA, Rajesh Phatale, MD, Aditi Joshi, BAMS, Kannan Subramanian, MD DM, MBBS

Blood (2018) 132 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2018-99-116160

Published: 2018

Journal Articles

Meaningful Reduction of Annual Bleeding Rate with Lower Dose Prophylaxis in Minimally Treated Children with Hemophilia in India

Aby Abraham, MD DM, Shashikant Apte, MD FRCPA, Abraham Sunder Singh, BSc, Kannan Subramaniam, DNB, DM, Anu Korula, MD DM, Aditi Joshi, BAMS, Dipti Khedekar, BA, Kavitha M Lakshmi, MSc, Biju George, MDDM, Vikram Mathews, MD DM, Alok Srivastava, MD

Blood (2017) 130 (Supplement 1): 1079.

https://doi.org/10.1182/blood.V130.Suppl_1.1079.1079

Published: 2017

Journal Articles

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Flora Peyvandi, MD PhD, Pier Mannuccio Mannucci, MD, Isabella Garagiola, PhD, Mohsen Elalfy, MD, Amal El-Beshlawy, MD, Madatha V. Ramanan, MD, Peyman Eshghi, MD, Suresh Hanagavadi, Ramabadran Varadarajan, MD, Mehran Karimi, MD, Mamta V. Manglani, MD, Cecil Ross, MD, Guy Young, MD, Tulika Seth, MD, Shashikant Apte, MD FRCPA, Dinesh M. Nayak, MD, Adriana C. Sandoval Gonzales, MD, Elena Santagostino, MD PhD, Maria Elisa Mancuso, MD PhD, Johnny N. Mahlangu, MD, Santiago Bonanad, PhD, Monica Cerqueira, MD, Nadia P. Ewing, MD, Christoph Male, MD MSC, Tarek Owaidah, MD FRCPA, Veronica Soto Arellano, MD, Nathan L. Kobrinsky, MD FRCP, Suvankar Majumdar, MD, Rosario Perez Garrido, MD, Anupam Sachdeva, Mindy Simpson, MD FAAP, Mathew Thomas, Ezio Zanon, MD, ALI Bulent Antmen, Kaan Kavakli, MD, Marilyn Manco-Johnson, MD, Monica Martinez, MD, Esperanza Marzouka, MS, PS, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Angeles Palomo Bravo, MD, Rogelio Paredes Aguilera, MD, Alessandra Nunes Loureiro Prezotti, MD, Schmitt Klaus, MD, Brian M. Wicklund, MD MPH, Bulent Zulfikar, MD, Rosendaal R. Frits, MD PhD

Blood (2015) 126 (23): 5.

https://doi.org/10.1182/blood.V126.23.5.5

Published: 2015

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India

Fouzia NA, Dip NB, DM,, Revathi Raj, MD, Dharma Choudhary, MD DM, Sharat Damodar, MD DM, Shashikant Apte, MD FRCPA, M Joseph John, MD DM, Ashish Dixit, MD DM, Kannan Subramanyan, DipNB, DM, Jose Easow, MD, Sunil Bhat, MBBS, MD FPHO, Chepsy C Philip, MD DM, Amrith Mathew, MD, Kavitha M Lakshmi, MSc, Anu Korula, MD DM, Aby Abraham, MD DM, Auro Viswabandya, MD DM, Alok Srivastava, MD FRACP

Blood (2015) 126 (23): 3219.

https://doi.org/10.1182/blood.V126.23.3219.3219

Published: 2015

Journal Articles

Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience

Biju George, DM, Manoranjan Mahapatra, Pravas Mishra, DM, Shashikant Apte, MD FRCPA, Sharat Damodar, MD DM, Navin Khattry, MDDM, Dharma Choudhary, MD DM, Jose Easow, MD, Revathi Raj, Tulika Seth, MD, Soniya Nityanand, MDPhD, Pankaj Malhotra, MD Additional Professor, Dinesh Bhurani, MD, Ashish Dixit, MD DM, Ajay Sharma, MD, Anupam Chakrapani, MBBS, MD DM, Sameer Ramesh Melinkeri, MD, Joseph M John, DM, Sunil Bhat, MBBS, MD FPHO, Neeraj Sidharthan, Bhausaheb Bagal, MD DM, Aby Abraham, MD DM, Ramesh Nimmagadda, T Raja, Abhijeet Ganapule, DM, V Lakshmanan, Fouzia Nambiathayil Abubacker, DM, Anu Korula, MD DM, Satyaranjan Das, Sanjeevan Sharma, Kannan Subramaniam, Rayaz Ahmed, MDDM, Narendra Agarwal, Alka Khadwal, MD, Gaurav Prakash, MBBS, MD DM, Amit Rauthan, DM, Chirag Shah, Uday Deotare, MD DM, MBBS, MNAMS, Sanjeev Kumar Sharma, MD DM, Seema S. Bhatwadekar, MD, Chandran K Nair, MD, Kavitha Lakshmi, MSc, Velu Nair, Mammen Chandy, MD, Alok Srivastava, MD FRACP, Vikram Mathews, DM

Blood (2015) 126 (23): 4386.

https://doi.org/10.1182/blood.V126.23.4386.4386

Published: 2015

Journal Articles

Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India

Blood (2014) 124 (21): 2462.

https://doi.org/10.1182/blood.V124.21.2462.2462

Published: 2014

Journal Articles

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Blood (2014) 123 (3): 317–325.

https://doi.org/10.1182/blood-2013-10-529974

Published: 2014

Includes: Supplemental data

Journal Articles

Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors

Sachin David, MSc, Vikram Mathews, Shashikant Apte, MD, Giridhara R Jayandharan, Ph.D, Sukesh C Nair, MD, Dolly Daniel, MD, Suresh Kumar, MSc, Ansu Abu Alex, MSc, Saravanan Ganesan, MSc, Kannan Subramanian, MD, Rayaz Ahmed, MD, Aby Abraham, MD, Auro Viswabandya, MD, Biju George, MD, Alok Srivastava, MD

Blood (2012) 120 (21): 3380.

https://doi.org/10.1182/blood.V120.21.3380.3380

Published: 2012

Journal Articles

IB1001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B.

Edward D. Gomperts, MD, Shashikant Apte, MD, Utpal Chaudhuri, MD, Joseph M John, MD, Vijay Ramanan, MD, Ri Liesner, MA MBBChir MD FRCP FRCPath MRCPCH, Amy D. Shapiro, MD, Bonnie J. Mills, PhD, Martin Lee, PhD

Blood (2012) 120 (21): 2225.

https://doi.org/10.1182/blood.V120.21.2225.2225

Published: 2012

Journal Articles

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

Vikram Mathews, MD, Biju George, MD, Farah Jijina, MD, Cecil Ross, MD, Reena Nair, MD, Shashikant Apte, MD, Geetha Narayanan, MD, Atul Sharma, MD, Kavitha M Lakshmi, MSc, Auro Viswabandya, MD, Ezhilarasi Chendamarai, MSc, Poonkuzhali Balasubramanian, Ph.D, Vivi Srivastava, MD, Mammen Chandy, MD, Alok Srivastava, MD

Blood (2011) 118 (21): 426.

https://doi.org/10.1182/blood.V118.21.426.426

Published: 2011

Journal Articles

A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia.

Mammen Chandy, Biju George, Vikram Mathews, MD, Shashikant Apte, MD, Velu Nair, Uday Deotare, MD, DM, Rajasekhar Thiurgnanam, Anjali Jaydeep Kelkar, MD, MNAMS, MBBS, Samir Melinkeri, Satyaranjan Das, Ajay Sharma, Auro Viswabandhya, Alok Srivastava, MD

Blood (2009) 114 (22): 1194.

https://doi.org/10.1182/blood.V114.22.1194.1194

Published: 2009

NARROW

Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study

Efficacy and Safety of Concizumab Prophylaxis in Patients with Hemophilia A or B without Inhibitors: 56-Week Cut-Off Results of the Phase 3 explorer8 Study

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India

Bilateral, Simultaneous Total Knee Replacement (TKR) Surgery for Hemophilia a with Eloctate (Extended Half Life Product)—A Feasible and Cost Effective Approach

Meaningful Reduction of Annual Bleeding Rate with Lower Dose Prophylaxis in Minimally Treated Children with Hemophilia in India

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India

Improved Outcomes with Allogeneic Stem Cell Transplantation for Aplastic Anaemia Using HLA Identical Sibling Donors: The Indian Stem Cell Transplant Registry (ISCTR) Experience

Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors

IB1001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B.

Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia

A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only